Healthcare -
Biotechnology - NASDAQ - IL
$ 8.13
-3.29 %
$ 22.6 M
Market Cap
-1.73
P/E
1. INTRINSIC VALUE
Balance Sheet
Sol-Gel Technologies Ltd.
| Current Assets | 31.3 M |
| Cash & Short-Term Investments | 23.9 M |
| Receivables | 3.6 M |
| Other Current Assets | 3.77 M |
| Non-Current Assets | 4.55 M |
| Long-Term Investments | 2.32 M |
| PP&E | 1.63 M |
| Other Non-Current Assets | 608 K |
| Current Liabilities | 5.28 M |
| Accounts Payable | 1.26 M |
| Short-Term Debt | 430 K |
| Other Current Liabilities | 3.59 M |
| Non-Current Liabilities | 1.71 M |
| Long-Term Debt | 878 K |
| Other Non-Current Liabilities | 833 K |
EFFICIENCY
Earnings Waterfall
Sol-Gel Technologies Ltd.
| Revenue | 11.5 M |
| Cost Of Revenue | 233 K |
| Gross Profit | 11.3 M |
| Operating Expenses | 23.3 M |
| Operating Income | -12 M |
| Other Expenses | -1.43 M |
| Net Income | -10.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sol-Gel Technologies Ltd.
| Net Income | -10.6 M |
| Depreciation & Amortization | 233 K |
| Capital Expenditures | -2 K |
| Stock-Based Compensation | 0 |
| Change in Working Capital | -4.4 M |
| Others | -1.1 M |
| Free Cash Flow | -13.9 M |
Wall Street Analysts Price Targets
Sol-Gel Technologies Ltd.
SLGL has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
SLGL does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Sol-Gel Technologies Ltd.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sol-Gel Reports First Quarter 2025 Results
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025.
globenewswire.com
- 2 months ago
Sol-Gel Announces Reverse Share Split
NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the Company's issued and outstanding ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share.
globenewswire.com
- 2 months ago
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Sol-Gel to receive $16 million during 2025 Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO.
globenewswire.com
- 3 months ago
Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis
This detailed market intelligence publication offers valuable insights into the innovative technologies, competitive landscape, and emerging opportunities that are reshaping the global surface engineering industry through 2035. This detailed market intelligence publication offers valuable insights into the innovative technologies, competitive landscape, and emerging opportunities that are reshaping the global surface engineering industry through 2035.
globenewswire.com
- 3 months ago
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know
Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners.
zacks.com
- 5 months ago
Is SolGel Technologies (SLGL) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
- 7 months ago
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know
SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 8 months ago
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.13.
zacks.com
- 8 months ago
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholders Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated SGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update.
globenewswire.com
- 8 months ago
SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for SolGel Technologies (SLGL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
zacks.com
- 10 months ago
All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy
SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
- 11 months ago
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve® Cream (roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories NESS ZIONA, Israel, Aug. 17, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.
globenewswire.com
- 11 months ago
8. Profile
Summary
Sol-Gel Technologies Ltd. SLGL
COUNTRY
IL
INDUSTRY
Biotechnology
MARKET CAP
$ 22.6 M
Dividend Yield
0.00%
Description
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Contact
7 Golda Meir Street, Ness Ziona, 7403650
https://www.sol-gel.com
IPO
Date
Feb. 1, 2018
Employees
34
Officers
Ms. Tamar Fishman Jutkowitz
Vice President & General Counsel
Mr. Eyal Ben-Or
Chief Financial Officer
Mr. Moshe Arkin
Chief Executive Officer & Executive Chairman
Dr. Itzik Yosef
Chief Operating Officer
Mr. Michael Glezin
Chief Business Officer